OBJECTIVES: Current literature lacks detailed understanding of the reimbursement framework of medication adherence enhancing interventions (MAEIs). As part of the ENABLE COST Action (CA19132), the EUREcA (EUropen REimbursement strategies for interventions targeting medication Adherence) study aims to fill in this gap and provide an in-depth overview of reimbursed MAEIs currently available in European countries at national and regional levels.

METHODS: The questionnaire for this cross-sectional, web-based survey was developed as a result of an iterative process of discussion informed by a desk review. Four external experts helped in the validation process. The study has been approved by the Ethical Committee of the Medical University of Lodz. This survey will be reported according to the CHERRIES guideline.

RESULTS: The desk review proved that the current literature is scarce in addressing reimbursement policies of MAEIs. Therefore, a 15-item questionnaire exploring details of reimbursed MAEIs was developed. Important concepts were explained in the introduction to ensure that respondents share the same theoretical frame. The survey has been made available online in June 2021 and has targeted ENABLE collaborators (mainly healthcare providers, competent authorities’ professionals, and academics with a medical or pharmaceutical background) in 38 European countries and Israel.

CONCLUSIONS: By providing a snapshot of the current European reimbursement landscape of MAEIs, EUREcA will help to identify availability of reimbursement models as well as gaps. Our findings will create firm background for the discussion on the implementation of MAEIs and the development of related reimbursement models to be part of health or medicine policies in Europe.